Hypocalcemia has been reported in~50% of patients 22q11.2DS and calcium regulation is known to play a role in neuronal development and synaptic plasticity. Because calcium ions play a role in neuronal function and development, we hypothesized that hypocalcemia would be associated with adverse effects on full scale IQ index (FSIQ) in patients with 22q11.2DS. A retrospective chart review cataloguing the presence or absence of hypocalcemia in 1073 subjects with a laboratory confirmed chromosome 22q11.2 deletion evaluated at the Children's Hospital of Philadelphia was conducted. 852/1073 patients had an endocrinology evaluation with laboratory confirmed calcium levels. 466/852 (54.7%) had a diagnosis of hypocalcemia. 265/1073 subjects ranging from 0 to 51 years of age had both calcium levels measured and a neuropsychological evaluation yielding a FSIQ. The mean FSIQ for 146/265 patients with hypocalcemia was 77.09 (SD = 13.56) and the mean FSIQ for 119/265 patients with normocalcemia was 77.27 (SD = 14.25). The distribution of patients with intellectual disability (ID) (FSIQ<69), borderline IQ , and average IQ (FSIQ>80) between the hypocalcemic and normocalcemic groups was not statistically significant (χ2 = 0.2676, p = 0.8748). Neonatal hypocalcemic seizures were not found to be associated with ID. We found no difference in FSIQ between the hypocalcemic and non-hypocalcemic patients with 22q11.2DS. As our findings differ from a previous report in adult subjects, we speculate that this may reflect a potential benefit from early treatment of hypocalcemia and may support early 22q11.2 deletion detection in order to offer prompt diagnosis and subsequent treatment of hypocalcemia.
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K E Y W O R D S
22q11.2 deletion syndrome, cognitive, DiGeorge syndrome, endocrine, hypocalcemia, intellectual disability 1 | INTRODUCTION Chromosome 22q11.2 deletion syndrome (22q11.2DS) is the most frequent cause of DiGeorge syndrome, velocardiofacial syndrome, and conotruncal anomaly face syndrome, and is the most common microdeletion syndrome known in humans. This copy number variant (CNV) usually occurs as a de novo event, most likely related to Low copy repeats (LCRs) that predispose the region to nonallelic meiotic recombination. However, approximately 10% of patients have inherited this mutation from an affected parent [McDonald-McGinn et al., 2001; McDonald-McGinn et al., 2015; Scambler, 2000] . The prevalence of 22q11.2DS has been reported to be between 1/3000-1/6000 live births, but more recently was found in~1/1000 unselected fetuses, specifically, those without congenital heart disease (CHD) or palatal anomalies seen on ultrasound, rendering it one of the most common chromosomal conditions in humans (Grati et al., 2015; McDonald-McGinn et al., 2015) . The clinical presentation of Abbreviations: 22q11.2DS, 22q11.2 deletion syndrome; CHD, Congenital heart disease; CNV, Copy number variant; FSIQ, Full scale IQ; LCR, Low copy repeat 22q11.2DS is highly variable including multiple organ system involvement with manifestations that vary in presence and severity. Most frequent physical and cognitive characteristics include CHD, immunodeficiency, hypocalcemia, palatal differences, gastrointestinal problems, renal anomalies, skeletal abnormalities, cognitive deficits, and behavioral differences including high rates of psychiatric illness (McDonald-McGinn et al., 2001; McDonald-McGinn et al., 2015) .
Similarly to the overall clinical presentation of patients with 22q11.2DS, endocrine manifestations are highly variable, the most common being hypocalcemia, which is generally attributed to hypoparathyroidism. The prevalence of hypocalcemia has been reported to range from 17 to 60% (Kapadia, Kim, McDonald-McGinn, Zackai, & Katz, 2008; Bassett et al., 2011; McDonald-McGinn et al., 2015) .
Symptoms of hypocalcemia can include seizures, feeding difficulties, tetany, stridor, and fatigue. In 22q11.2DS, hypocalcemia is often transient in the neonatal period, however, it can recur during times of stress, including perioperatively or during illness [Bassett et al., 2011; Cheung, George, Costain, et al., 2014; De Smedt, Swillen, Verschaffel, & Ghesquiere, 2009; McDonald-McGinn et al., 2001; McDonald-McGinn et al., 2015] .
The pharyngeal pouches give rise to the superior and inferior parathyroid glands. The pharyngeal pouch expands during the sixth week of development and begins to differentiate into an inferior parathyroid gland. T-box protein 1 (TBX1) is required for the development of the pharyngeal pouches, is located within the LCR22A-LCR22B region of chromosome 22q11.2, and is missing in the presence of a standard LCR22A-LCR22D or proximally nested 22q11.2 LCR22A-LCR22B deletion. Studies have suggested that genes located in the typically deleted region, such as TBX1, influence the development of the parathyroid glands McDonald-McGinn et al., 2015; Merscher et al., 2001; Taddei, Morishima, Huynh, & Lindsay, 2001; Scambler, 2000; Yagi et al., 2003) .
As variable expressivity has been reported with 22q11.2DS, it is important to study phenotype-phenotype correlations, specifically here, the effect of hypocalcemia on cognitive deficits. As with nearly all other clinical manifestations in patients with 22q11.2DS, cognitive . Although some patients have more severe intellectual disability, it is rare and present in less than 10% of patients (Biswas & Furniss, 2016; Evers et al., 2014; McDonald-McGinn et al., 2015) .
Despite numerous reports on associated findings in 22q11.2DS, specific examination of endocrine manifestations is limited, including the relationship between hypocalcemia and full scale IQ (FSIQ) levels. The present study aims to examine the relationship between hypocalcemia and FSIQ levels in a large cohort of primarily pediatric patients with 22q11.2DS who were identified in childhood.
| MATERIALS AND METHODS

| Subjects
We retrospectively reviewed the patient records of 1,073 patients with 22q11.2DS (ages 0-51 years) followed in the 22q and You Center at The Children's Hospital of Philadelphia, a multidisciplinary clinic for children and adults with 22q11.2DS. Written informed consent was obtained and this study was performed with approval from The Children Hospital of Philadelphia and Arcadia University's Institutional Review Board as part of a genetic counseling thesis project. The chromosome 22q11.2 deletion was confirmed in all patients by standard fluorescence in situ hybridization (FISH), array comparative genomic hybridization (CGH), multiplex ligation probe-dependent amplification (MLPA), and/or genome wide microarray. Demographic information of the subjects is presented in Table 1 .
| Methods
Medical records were reviewed for demographics and lifetime laboratory measurements including ionized calcium and serum calcium, age, and treatment, where available. As the guidelines for managing patients with 22q11.2DS were published in 2011, not all patients underwent routine screening for hypocalcemia. Subjects were considered to have hypocalcemia if laboratory evidence was available in the 
| Statistical analyses
Pearson's chi-squared test was used to statistically analyze the data.
3 | RESULTS Of the patients with normocalcemia, 167 were considered normocalcemic based on one laboratory measurement.
| Calcium values
Of the 466 patients with a history of hypocalcemia, 444 had a confirmed age of onset, including; 282 (63.5%) diagnosed in infancy (0-1 year), 130 (29.3%) diagnosed in childhood (1-18 years), and 32 (7.2%) diagnosed in adulthood (>18 years). 
| Calcium levels and deletion size
The presence of hypocalcemia was compared with deletion size (Table 3) Of the 54 patients with atypical nested deletions, 27 were LCR22A-LCR22B (50%), 6 were LCR22A-LCR22C (11.1%), 13 were LCR22B-LCR22D (24.1%), 6 were LCR22C-LCR22D (11.1%), one was LCR22C-LCR22E (1.9%), and one was LCR22D-E (1.9%) (Table 3 ). 14/27 (51.9%) patients with LCR22A-B had a diagnosis of hypocalcemia and 13/27 (48.1%) had normal calcium levels. 5/6 (83.3%) patients with LCR22A-LCR22C had a diagnosis of hypocalcemia and 1/6 (16.7%) had normal calcium levels. 2/13 (15.4%) patients with LCR22B-LCR22D had a diagnosis of hypocalcemia and 11/13 (84.6%) had normal calcium levels. 3/6 (50%) patients with LCR22C-LCR22D had a diagnosis of hypocalcemia and 3/6 (50%) had normal calcium levels.
| Calcium levels and FSIQ scores
Of the 852 patients with an endocrinology evaluation with laboratory confirmed calcium levels, 265 also had a neuropsychology evaluation yielding a full scale IQ index (FSIQ); 146 (55.1%) with a diagnosis of hypocalcemia and 119 (44.9%) with normal calcium levels. Of the 146 with hypocalcemia, 74 (50.7%) were male, and 72 (49.3%) were female.
In assessing cognitive outcomes, patients with multiple IQ assessments were assigned a singular mean score yielding a FSIQ. Calcium levels and FSIQ scores were assessed in relation to deletion size (Table 4) . For subjects with a LCR22A-LCR22D and hypocalcemia (n = 138), the mean FSIQ was 77.09 (SD = 13.56). For subjects with a LCR22A-LCR22D and normal calcium levels (n = 112), the FSIQ was 77.27 (SD = 14.36). For subjects with a LCR22A-LCR22B and hypocalcemia (n = 14), the mean FSIQ was 88.50 (SD = 9.29). For subjects with a LCR22A-LCR22B and normal calcium levels (n = 13), the mean FSIQ was 83.75 (SD = 9.88).
Of the 146 subjects with hypocalcemia, 38 (26%) had intellectual Infancy (0-1 years of age); Juvenile (1-18 years of age); Adulthood (>18 years of age). 
| FSIQ scores and neonatal Hypocalcemic seizure
Of the 146 patients with hypocalcemia and FSIQ data, 15 (10.3%) had at least one neonatal hypocalcemic seizure. The mean FSIQ for these patients was 77.60 (SD = 15.8) and specifically 4 (26.7%) had ID, 4 (26.7%) had borderline intelligence, and 7 (46.6%) had an average FSIQ.
| DISCUSSION
Hypocalcemia has been reported in~50% of patients with 22q11.2DS. Consistent with the literature, we found hypocalcemia to be present in 54.7% of patients with 22q11.2DS in our larger cohort.
From a neurocognitive perspective, mild to moderate ID has been observed in~1/3 of patients with 22q11.2DS, whereas, severe ID is quite rare (Evers et al., 2014; .
We identified ID in 24.9% of the subset of our cohort where calcium levels and FSIQ measures were available. This frequency of ID is less than what would have been expected from the literature, which it is unclear why this is.
In a retrospective study, Cheung, et al., previously reported neonatal seizures, likely due to hypocalcemia, positively associated with intellectual disability in adults with 22q11.2DS Cheung, George, Costain, et al., 2014 ). In contrast, our study found no association between hypocalcemic seizures and FSIQ scores. Moreover, we found no statistically significant difference in FSIQ between our large primarily pediatric cohort of patients with 22q11.2DS with or without hypocalcemia. Thus, we wonder if early identification of hypocalcemia may, with appropriate therapeutic intervention, provide a potential long term cognitive benefit.
Calcium ions are secondary messengers that transfer signals carried by extracellular molecules to a wide range of intracellular target molecules in all cells, including neurons in the brain. In neurons, calcium ions play an important role in controlling neuronal excitability and regulating activity-dependent signaling (Gleichmann & Mattson, 2011) . It has been proposed that because calcium has been shown to influence neurodevelopment, there is a possibility that dysregulation of calcium could play a role in lower IQ levels Cheung, George, Costain, et al., 2014; Muldoon et al., 2014) . Interestingly, calcium signaling pathways have been shown to regulate neuronal functions that have been implicated in other neurodevelopmental disorders, such as bipolar disorder, schizophrenia, and autism spectrum disorder, further suggesting that calcium levels could have an influence on the neurodevelopmental phenotype in 22q11.2DS (Berridge, 2014; Schmunk & Gargus, 2013) .
Limitations of our study include lack of calcium and FSIQ data for our entire cohort. The international 22q11.2 healthcare community created guidelines for patients with 22q11.2DS, which were published in 2011 (Bassett et al., 2011) . These guidelines recommended calcium levels be assessed at the time of diagnosis, in infancy every 3 to 6 months, then every 5 years through childhood, and every 1-2 years thereafter adding assments at time of stress, such as perioperatively and at times of illness. There are no set guidelines for when or how to administer standardized psychometric testing in these guidelines (Bassett et al., 2011) . Because these guidelines were not published until 2011, not all of the patients in our study had records of Another limitation is that if the patients were not followed at The
Children's Hospital of Philadelphia, it is likely that they did not receive standardized psychometric testing or it was not available for our review. This is because current guidelines recommend assessing development and school performance, however, there is not a specific test recommended. Unfortunately, we also did not have treatment records for all of the patients who were found to have hypocalcemia, but we assume that if an individual was found to have hypocalcemia, then they were treated. Similarly, we do not have records for all treatment, severity, and duration of neonatal seizures.
Future studies prospectively screening all patients with 22q11.2DS for hypocalcemia and FSIQ are warranted to better understand the relationship between hypocalcemia/hypocalcemic seizures and long-term cognitive outcome. In the interim, based on our and other reports noting hypocalcemia in at least 50% of patients with 22q11.2DS, and as has been suggested by the international 22q11.2 healthcare community vis-à-vis their practical healthcare guidelines, testing for hypocalcemia is indicated in all patients with 22q11.2DS at diagnosis and routinely thereafter including at times of biological stress, for example, during illness, perioperatively, during puberty, and during pregnancy (Bassett et al., 2011; McDonald-McGinn et al., 2015) . Hence, early diagnosis of 22q11.2DS, utilizing routine prenatal/neonatal screening methodologies, is paramount in supporting such identification and early treatment (Bassett et al., 2011; McDonald-McGinn et al., 2015) . Infancy (0-1 years of age); Juvenile (1-18 years of age); Adulthood (>18 years of age).
